In the preceding three months, 5 analysts have released ratings for PROCEPT BioRobotics (NASDAQ:PRCT), presenting a wide array of perspectives from bullish to bearish. In the table below, you'll find ...
Analysts' ratings for PROCEPT BioRobotics (NASDAQ:PRCT) over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a concise overview of recent ratings by ...
Throughout the last three months, 7 analysts have evaluated PROCEPT BioRobotics (NASDAQ:PRCT), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed view of ...
Forbes contributors publish independent expert analyses and insights. I write about biodiversity and the hidden quirks of the natural world. Over 390 million years ago, the ancestors of modern land ...
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. PROCEPT BioRobotics (PRCT) is back in focus after its Q4 2025 revenue miss, softer ...
NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative ...
SAN JOSE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (“the Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results